Duplicated membrane estrogen receptors in the European sea bass (Dicentrarchus labrax): Phylogeny, expression and regulation throughout the reproductive cycle

The numerous estrogen functions reported across vertebrates have been classically explained by their binding to specific transcription factors, the nuclear estrogen receptors (ERs). Rapid non-genomic estrogenic responses have also been recently identified in vertebrates including fish, which can be mediated by membrane receptors such as the G protein-coupled estrogen receptor (Gper). In this study, two genes for Gper, namely gpera and gperb, were identified in the genome of a teleost fish, the European sea bass. Phylogenetic analysis indicated they were most likely retained after the 3R teleost-specific whole genome duplication and raises questions about their function in male and female sea bass. Gpera expression was mainly restricted to brain and pituitary in both sexes while gperb had a widespread tissue distribution with higher expression levels in gill filaments, kidney and head kidney. Both receptors were detected in the hypothalamus and pituitary of both sexes and significant changes in gpers expression were observed throughout the annual reproductive season. In female pituitaries, gpera showed an overall increase in expression throughout the reproductive season while gperb levels remained constant. In the hypothalamus, gpera had a higher expression during vitellogenesis and decreased in fish entering the ovary maturation and ovulation stage, while gperb expression increased at the final atresia stage. In males, gpers expression was constant in the hypothalamus and pituitary throughout the reproductive cycle apart from the mid- to late testicular development stage transition when a significant up-regulation of gpera occurred in the pituitary. The differential sex, seasonal and subtype-specific expression patterns detected for the two novel gper genes in sea bass suggests they may have acquired different and/or complementary roles in mediating estrogens actions in fish, namely on the neuroendocrine control of reproduction.info:eu-repo/semantics/publishedVersio

Apoyo social formal en colectivos con dificultades de inserción laboral

IX Jornades de Foment de la Investigació de la FCHS (Any 2003-2004

Peculiar objects towards 3FGL J0133.3+5930: an eclipsing Be star and an active galactic nucleus

Aims. We aim to contribute to the identification of unassociated gamma-ray sources in the galactic plane in order to enlarge the currently known population of gamma-ray binaries and related systems, such as radio emitting X-ray binaries and microquasars. These objects are currently regarded as excellent test beds for the understanding of high energy phenomena in stellar systems. Methods. Potential targets of study are selected based on cross-identification of the 3rd Fermi Large Area Telescope catalogue with historical catalogues of luminous stars often found as optical counterparts in known cases. Follow-up observations and analysis of multi-wavelength archival data are later used to seek further proofs of association beyond the simple positional agreement. Results. Current results enable us to present here the case of the Fermi source 3FGL J0133.3+5930 where two peculiar objects have been discovered inside its region of uncertainty. One of them is the star TYC 3683-985-1 (LS I +59 79) whose eclipsing binary nature is reported in this work. The other one is the X-ray source SWIFT J0132.9+5932, that we found to be a likely low-power Active Galactic Nucleus at z = 0:1143 \pm 0:0002. If this second object is of blazar type, it could easily account for the observed gamma-ray photon flux. However, this is not confirmed at present, thus rendering still open the star system TYC 3683-985-1 as an alternative counterpart candidate to the Fermi source.Comment: 8 pages; 10 figures; accepted for publication in Astronomy & Astrophysic

High In-content InGaN layers synthesized by plasma-assisted molecular-beam epitaxy: growth conditions, strain relaxation and In incorporation kinetics

We report the interplay between In incorporation and strain relaxation kinetics in high-In-content InxGa1-xN (x = 0.3) layers grown by plasma-assisted molecular-beam epitaxy. For In mole fractions x = 0.13-0.48, best structural and morphological quality is obtained under In excess conditions, at In accumulation limit, and at a growth temperature where InGaN decomposition is active. Under such conditions, in situ and ex situ analysis of the evolution of the crystalline structure with the growth thickness points to an onset of misfit relaxation after the growth of 40 nm, and a gradual relaxation during more than 200 nm which results in an inhomogeneous strain distribution along the growth axis. This process is associated with a compositional pulling effect, i.e. indium incorporation is partially inhibited in presence of compressive strain, resulting in a compositional gradient with increasing In mole fraction towards the surface

Las revistas científicas en el ámbito de la Actividad Fisica y el Deporte en Journal Citation Reports (JCR)

El factor de impacto mide la repercusión que ha tenido una revista en la literatura científica mediante el recuento de las citas que ha recibido. A pesar de sus limitaciones, las agencias de evaluación de algunos países, entre ellos España, lo utilizan en la valoración de la actividad investigadora. El propósito del presente ha sido examinar el factor de impacto de las revistas de Ciencias del Deporte y su posición en su área. También se han analizado las revistas españolas en las que se publican trabajos relacionados con las Ciencias del Deporte

Protocol for regional implementation of collaborative lung function testing

The potential of forced spirometry (FS) testing for diagnosis, monitoring and management of chronic respiratory patients is well established1-3 such that FS is a pivotal test in both respiratory medicine and primary care. Moreover, it also shows potential in the informal care scenario: that is, in pharmacy offices for case-finding purposes4,5 and for self-management in selected patients.6,7 We acknowledge that well-designed studies8 have failed to show practical benefits of FS for asthma and COPD diagnosis and management in primary care. However, it has been demonstrated that historical limitations for extensive use of FS in primary care, because of suboptimal quality of testing, can be overcome by offline remote support by specialised professionals.9,10 Large-scale deployment of this type of setting has generated evidence of cost-effectiveness.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival : an updated analysis of KEYNOTE-010 trial

Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes in patients based on PD-L1 expression in archival versus newly collected tumor samples using recently updated survival data. Patients and methods: PD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) in archival or newly collected tumor samples. Patients received pembrolizumab 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W for 24 months or until progression/intolerable toxicity/other reason. Response was assessed by RECIST v1.1 every 9 weeks, survival every 2 months. Primary end points were OS and progression-free survival (PFS) in tumor proportion score (TPS) 50% and 1%; pembrolizumab doses were pooled in this analysis. Results: At date cut-off of 24 March 2017, median follow-up was 31 months (range 23-41) representing 18 additional months of follow-up from the primary analysis. Pembrolizumab versus docetaxel continued to improve OS in patients with previously treated, PD-L1-expressing advanced NSCLC; hazard ratio (HR) was 0.66 [95% confidence interval (CI): 0.57, 0.77]. Of 1033 patients analyzed, 455(44%) were enrolled based on archival samples and 578 (56%) on newly collected tumor samples. Approximately 40% of archival samples and 45% of newly collected tumor samples were PD-L1 TPS 50%. For TPS 50%, the OS HRs were 0.64 (95% CI: 0.45, 0.91) and 0.40 (95% CI: 0.28, 0.56) for archival and newly collected samples, respectively. In patients with TPS 1%, OS HRs were 0.74 (95% CI: 0.59, 0.93) and 0.59 (95% CI: 0.48, 0.73) for archival and newly collected samples, respectively. In TPS 50%, PFS HRs were similar across archival [0.63 (95% CI: 0.45, 0.89)] and newly collected samples [0.53 (95% CI: 0.38, 0.72)]. In patients with TPS 1%, PFS HRs were similar across archival [0.82 (95% CI: 0.66, 1.02)] and newly collected samples [0.83 (95% CI: 0.68, 1.02)]. Conclusion: Pembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of patients with newly collected and archival samples